{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260612633536/en/TRUQAP%C2%AE-capivasertib-combination-approved-in-the-US-as-first-and-only-targeted-treatment-for-PTEN-deficient-metastatic-hormone-sensitive-prostate-cancer", "message": "News view counter 798163 successfully enlarged"}